Company news

SeaStar Medical Holding Corporation news in 2026

SeaStar Medical Holding Corporation's news releases, calls and decks from 2026, newest first.

View company

SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026

November 4, 2026

FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

November 3, 2026

SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI

October 22, 2026

SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award

October 14, 2026

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

October 7, 2026

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

October 5, 2026

SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

October 2, 2026

New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)

October 1, 2026

SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026

September 29, 2026

SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference

September 10, 2026

SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 12, 2026

SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026

August 6, 2026

SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)

July 14, 2026

SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury

June 23, 2026

SeaStar Medical to Present at Upcoming Investor Summit Conference

June 22, 2026

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

May 12, 2026

SeaStar Medical to Report First Quarter Financial Results on May 13, 2026

May 6, 2026

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

March 30, 2026

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

March 25, 2026

SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

March 18, 2026

SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th

March 9, 2026

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

March 5, 2026

ICU: Publication Validates Real-World Clinical Impact of QUELIMMUNE™ in Pediatric AKI

February 11, 2026

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

February 9, 2026

SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference

January 29, 2026

SeaStar Medical Announces 2026 Milestones

January 7, 2026

SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference

January 6, 2026

Calls in 2026

Decks in 2026